Printer Friendly

Articles from M2 Pharma (November 12, 2019)

1-14 out of 14 article(s)
Title Author Type Words
Akebia Partner Presents Positive 52-week Efficacy and Safety Data for Vadadustat from Two Pivotal Phase 3 Studies in Japanese Patients with Anemia Due to Chronic Kidney Disease. 941
Alnylam Initiates ILLUMINATE-C Phase 3 Study of Lumasiran for the Treatment of Advanced Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study. 672
ATAI Life Sciences partners with Cyclica to revolutionize drug development for mental health disorders. 214
BioTheryX names new director. 188
Five Prime Therapeutics Presents Initial Safety Data from the Phase 1 Trial of FPT155 at the Society for Immunotherapy of Cancer Annual Meeting. 498
Mesa Labs closes acquisition of Gyros Protein Technologies for cash consideration of USD180m. 194
Micreos announces grant of EUR2.5m for breakthrough skin problems under EU's Horizon 2020 funding. 225
Saniona reports recruitment of last patient in phase 2a study for Tesomet. Clinical report 243
Stone Capital collaborates with Biosyngen. 118
US FDA approves Celgene and Acceleron Pharma's Reblozyl. 200
US FDA supplemental New Drug Application submitted for AbbVie's IMBRUVICA in combination with rituximab. 217
Welltower closes acquisition of USD1.7bn Hammes and Class-A Properties. 227
Young Innovations acquires PuraGraft. 114
Young Innovations closes acquisition of PuraGraft. 123

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters